New York State Common Retirement Fund Sells 36,136 Shares of Organon & Co. (NYSE:OGN)

New York State Common Retirement Fund decreased its position in shares of Organon & Co. (NYSE:OGNFree Report) by 14.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 222,883 shares of the company’s stock after selling 36,136 shares during the period. New York State Common Retirement Fund owned about 0.09% of Organon & Co. worth $3,869,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Wellington Shields Capital Management LLC bought a new position in Organon & Co. in the 4th quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd increased its position in shares of Organon & Co. by 495.5% during the third quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares during the period. Northwest Capital Management Inc acquired a new stake in shares of Organon & Co. during the second quarter worth $32,000. Penserra Capital Management LLC acquired a new stake in shares of Organon & Co. during the second quarter worth $34,000. Finally, Glassman Wealth Services increased its position in shares of Organon & Co. by 36.8% during the second quarter. Glassman Wealth Services now owns 1,665 shares of the company’s stock worth $35,000 after buying an additional 448 shares during the period. Institutional investors and hedge funds own 77.08% of the company’s stock.

Organon & Co. Price Performance

OGN opened at $16.83 on Tuesday. The company’s 50-day moving average is $14.90 and its 200 day moving average is $16.51. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $29.55. The firm has a market capitalization of $4.30 billion, a P/E ratio of 7.35, a PEG ratio of 0.48 and a beta of 0.79.

Wall Street Analysts Forecast Growth

OGN has been the subject of a number of research reports. Piper Sandler reduced their price target on shares of Organon & Co. from $32.00 to $22.00 and set an “overweight” rating for the company in a report on Wednesday, November 22nd. The Goldman Sachs Group cut shares of Organon & Co. from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $33.00 to $16.00 in a report on Friday, November 3rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.33.

Get Our Latest Analysis on OGN

Organon & Co. Profile

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Featured Articles

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNFree Report).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.